AVEO Announces Closing of Public Offering of Common Stock and Partial Exercise of Option to Purchase Additional Shares
The net proceeds of the offering are expected to be used for working capital and general corporate purposes, including funding commercialization activities relating to tivozanib.
SVB Leerink and Stifel acted as joint bookrunning managers for the offering. Baird and
The shares were offered by AVEO pursuant to a shelf registration statement on Form S-3 that was filed with the
A final prospectus supplement relating to, and describing the terms of, the offering has been filed with the
Copies of the final prospectus supplement and the accompanying prospectus relating to this offering may also be obtained from
This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About
AVEO is developing an oncology pipeline designed to provide a better life for patients with cancer. AVEO’s strategy is to focus its resources toward development and commercialization of its product candidates in
Cautionary Note Regarding Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “hope,” “intend,” “may,” “plan,” “potential,” “could,” “should,” “would,” “seek,” “look forward,” “advance,” “goal,” “strategy,” or the negative of these terms or other similar expressions, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among others, statements relating to the intended use of proceeds from the public offering. Actual results may differ materially from those projected or implied in these forward-looking statements. You should not place undue reliance on these forward-looking statements. Factors that may cause such a difference include, without limitation, risks and uncertainties related to the impact of general economic, industry or political conditions in
View source version on businesswire.com: https://www.businesswire.com/news/home/20200619005391/en/
212-600-1902
aveo@argotpartners.com
Source: AVEO Oncology